Safety and efficacy of exenatide as monotherapy and adjunctive therapy to oral antidiabetic agents in adolescents with type 2 diabetes

Trial Profile

Safety and efficacy of exenatide as monotherapy and adjunctive therapy to oral antidiabetic agents in adolescents with type 2 diabetes

Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Exenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 17 Nov 2017 Planned End Date changed from 15 May 2020 to 6 Mar 2023.
    • 17 Nov 2017 Planned primary completion date changed from 17 Aug 2018 to 10 Mar 2020.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top